<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669134</url>
  </required_header>
  <id_info>
    <org_study_id>147-2015-PL</org_study_id>
    <nct_id>NCT02669134</nct_id>
  </id_info>
  <brief_title>CRT Improved Clinical Response UK Trial</brief_title>
  <acronym>CRICKET</acronym>
  <official_title>CRT Improved Clinical Response UK Trial: A Multi-centre, Prospective, Randomized, Cross-over, Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aston University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the CRICKET study is demonstrate that AV and VV optimization using SonR&#xD;
      improves LV reverse remodeling response to CRT, compared with 'Fixed Settings' (FS) after 6&#xD;
      months of treatment. In this investigator-initiated, multi-centre, 2:2 factorial design,&#xD;
      randomized, two-arm, double-blinded, cross-over, prospective trial, CRT recipients will be&#xD;
      randomized to 'SonR' atrioventricular (AV) and ventricular-ventricular (VV) optimization or&#xD;
      'fixed settings'. The primary endpoint is an absolute reduction in left ventricular&#xD;
      end-systolic volume.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator-initiated, multi-centre, 2:2 factorial design, randomized, two-arm,&#xD;
      double-blinded, cross-over, prospective trial&#xD;
&#xD;
      Main study objectives&#xD;
&#xD;
      The main objective of the CRICKET study is demonstrate that AV and VV optimization using SonR&#xD;
      improves LV reverse remodeling response to CRT, compared with 'Fixed Settings' (FS) after 6&#xD;
      months of treatment.&#xD;
&#xD;
      Study endpoints&#xD;
&#xD;
      Primary endpoint: The primary endpoint is a reduction (absolute difference) in LVESV with&#xD;
      SonR vs FS after 6 months of treatment. The difference intra-patient of absolute change of&#xD;
      LVESV value will be compared between two treatments: &quot;SonR optimization&quot; vs. &quot;FS&quot;, defined as&#xD;
      a sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous).&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
      Change in 6 MWT distance Change in NYHA class Change in quality of life Change in patient&#xD;
      global assessment (EQ-5D) Change in Quality of life (MLWHF questionnaire) Change in LVEF AF&#xD;
      burden Adverse Events&#xD;
&#xD;
      Number of subjects&#xD;
&#xD;
      Two hundred (200) patients will be enrolled. All patients will be implanted with the SonRtip&#xD;
      bipolar atrial lead and a LivaNova (Sorin) CRT-D device offering both SonR optimization&#xD;
      algorithm and atrio-biventricular pacing. Patients will be assigned to either the treatment&#xD;
      or control arms, employing a 1:1 randomization with up to 100 patients in each of the 2&#xD;
      groups: Study Group (SonR CRT Optimization programmed &quot;AV+VV&quot;) and Control Group (&quot;Fixed&#xD;
      Settings&quot; (FS), defined as a sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR&#xD;
      CRT Optimization programmed &quot;Off&quot;). After the first 6 months, patients will be crossed-over&#xD;
      to the alternative arm for another 6 months. There will be no washout period.&#xD;
&#xD;
      Duration of the clinical investigation&#xD;
&#xD;
      The study inclusion phase is expected to last approximately 1.5 years.&#xD;
&#xD;
      Follow-ups&#xD;
&#xD;
      Patients will be evaluated at baseline and randomized prior to implantation to SonR&#xD;
      optimization or FS. A further clinical assessment, ECG and echocardiography will be&#xD;
      undertaken at 6 months. At this point, patients will be crossed over to the other arm for&#xD;
      another 6 months. The study closes following a further clinical and echocardiographic&#xD;
      assessment at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular end-systolic volume (LVSV)</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction in LVESV with SonR vs FS after 6 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Walking distance on 6 -minute walk test</measure>
    <time_frame>6 months</time_frame>
    <description>Change in 6 MWT distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>6 months</time_frame>
    <description>Change in NYHA class</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - general (non-disease specific)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in quality of life, assessed using EQ-5D (section 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Change in patient global assessment (included in EQ-5D, section 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific quality of life (heart failure)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in quality of life (MLWHF questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Change in LVEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden</measure>
    <time_frame>6 months</time_frame>
    <description>AF burden according to mode-switches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>System safety assessed by Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Report all Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiac Failure</condition>
  <arm_group>
    <arm_group_label>SonR optimization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed &quot;AV+VV&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed settings</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming device programming: sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR CRT Optimization programmed &quot;Off&quot;).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Device programming</intervention_name>
    <description>SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed &quot;AV+VV&quot;</description>
    <arm_group_label>Fixed settings</arm_group_label>
    <arm_group_label>SonR optimization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for implantation of a CRT-D device according to current NICE or ESC&#xD;
             guidelines;&#xD;
&#xD;
          -  In sinus rhythm;&#xD;
&#xD;
          -  NYHA class II, III or IV&#xD;
&#xD;
          -  Have reviewed, signed and dated an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to do a 6 min walk test.&#xD;
&#xD;
          -  Previous implant with a pacemaker, an ICD or a CRT device (except upgrade from single&#xD;
             chamber ICD with a fully functional defibrillation lead) not under recall or&#xD;
             surveillance);&#xD;
&#xD;
          -  Persistent atrial arrhythmias (or cardioversion for atrial fibrillation) within the&#xD;
             past month;&#xD;
&#xD;
          -  Ventricular tachyarrhythmia of transient or reversible causes such as acute myocardial&#xD;
             infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte&#xD;
             imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;&#xD;
&#xD;
          -  Incessant ventricular tachyarrhythmia;&#xD;
&#xD;
          -  Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous&#xD;
             Coronary Intervention (PCI) within the past 4 weeks;&#xD;
&#xD;
          -  Correctable valvular disease that is the primary cause of heart failure;&#xD;
&#xD;
          -  Indication for valve repair or replacement;&#xD;
&#xD;
          -  Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the&#xD;
             previous 3 months);&#xD;
&#xD;
          -  On transplant waiting list;&#xD;
&#xD;
          -  Previous heart transplant;&#xD;
&#xD;
          -  Already included in another clinical study that could confound the results of this&#xD;
             study;&#xD;
&#xD;
          -  Life expectancy less than 1 year;&#xD;
&#xD;
          -  Inability to understand the purpose of the study;&#xD;
&#xD;
          -  Unavailability for scheduled follow-up or refusal to cooperate;&#xD;
&#xD;
          -  Age of less than 18 years;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Drug addiction or abuse;&#xD;
&#xD;
          -  Under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nichola Seare, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Aston University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Leyva, MD, FRCP</last_name>
    <phone>+44 1212043284</phone>
    <email>f.leyva@aston.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nichola Seare, PhD</last_name>
    <phone>+44 121 2043325</phone>
    <email>n.seare@aston.ac.uk</email>
  </overall_contact_backup>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2016</study_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiac resynchronization therapy</keyword>
  <keyword>optimization</keyword>
  <keyword>heart failure</keyword>
  <keyword>reverse left ventricular remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

